CMPX
Compass Therapeutics, Inc.Company Information
- Company Name
- Compass Therapeutics, Inc.
- CIK
- CIK0001738021
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CMPX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CMPX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-24
- Last sale
- 2025-04-09
- Shares purchased (TTM)
- 42,500
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 164,368,718
- Shares outstanding
- 186,798,000
- Ownership
- 87.99%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 20.60%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 35 | 55 | 31 | 46 | 23 | 41 | 43 | 19 | 19 | 43 | 24 | 30 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 181 | 196 | 210 | 221 | 106 | 124 | 133 | 141 | 154 | 159 | 154 | 167 | ||||||
| Marketable Securities Current | 144 | 140 | 178 | 174 | 78 | 72 | 83 | 99 | 127 | 133 | 128 | 133 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 5 | 12 | 6 | 6 | 7 | 2 | 1 | 3 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 8 | 9 | 9 | 9 | 10 | 7 | 7 | 7 | 1 | 1 | 2 | 2 | ||||||
| Restricted Cash | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets | 190 | 205 | 220 | 231 | 117 | 131 | 140 | 149 | 156 | 161 | 157 | 170 | ||||||
| Accounts Payable Current | 3 | 1 | 2 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 4 | 2 | ||||||
| Accrued Liabilities Current | 12 | 8 | 11 | 9 | 11 | 13 | 6 | 3 | 7 | 2 | 3 | 6 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 16 | 10 | 14 | 12 | 14 | 15 | 9 | 4 | 10 | 4 | 8 | 9 | ||||||
| Operating Lease Liability Current | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 8 | 8 | 9 | 9 | 10 | 6 | 6 | 6 | 0 | 0 | 1 | 1 | ||||||
| Liabilities | 24 | 19 | 23 | 22 | 23 | 21 | 15 | 11 | 10 | 4 | 8 | 10 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 641 | 636 | 628 | 625 | 494 | 491 | 490 | 488 | 485 | 483 | 464 | 462 | ||||||
| Stockholders Equity | 166 | 186 | 197 | 210 | 93 | 110 | 125 | 138 | 146 | 157 | 149 | 160 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -475 | -449 | -431 | -415 | -401 | -381 | -365 | -350 | -339 | -326 | -315 | -302 | ||||||
| Liabilities And Stockholders Equity | 190 | 205 | 220 | 231 | 117 | 131 | 140 | 149 | 156 | 161 | 157 | 170 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Shares Outstanding | 180 | 180 | 178 | 178 | 138 | 138 | 138 | 138 | 138 | 138 | 128 | 127 | ||||||
| Common Stock Shares Issued | 180 | 180 | 178 | 178 | 138 | 138 | 138 | 138 | 138 | 138 | 128 | 127 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCompass Therapeutics, Inc. (CMPX) — SEC Financial Statements & Analysis
Compass Therapeutics, Inc. (CMPX) is a biological products, (no diagnostic substances) company, incorporated in DE. Compass Therapeutics, Inc. trades on Nasdaq as: CMPX. Compass Therapeutics, Inc. (CMPX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Compass Therapeutics, Inc. carries a market cap of $409.09M, a P/E ratio of -5.57x, a P/B ratio of 2.46x, a P/S ratio of 309.00x, an enterprise value of $373.63M, and an EV/EBITDA multiple of -4.61x. On profitability, it posts an operating margin of -7273.06%, a net margin of -6496.59%, a Return on Equity (ROE) of -56.66%, a Return on Assets (ROA) of -47.87%, and a Return on Invested Capital (ROIC) of -80.70%. Per share, it reports EPS of $-0.39, diluted EPS of $-0.40, free cash flow per share of $-0.30, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 18.41% year-over-year, and EPS growth of -12.34% year-over-year. On the balance sheet, it maintains a current ratio of 11.22x, a quick ratio of 11.15x, working capital of $164.76M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, free cash flow of $-56.38M (TTM), and net debt of $-35.45M. Figures sourced from SEC EDGAR.
- Market Cap
- $409.09M
- P/E TTM
- -5.57x
- EPS TTM
- $-0.39
- P/B TTM
- 2.46x
- ROE TTM
- -56.66%
- ROA TTM
- -47.87%
- Debt To Equity
- 0.15x
- Free Cash Flow TTM
- $-56.38M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Compass Therapeutics, Inc. in?
Compass Therapeutics, Inc. (CMPX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CMPX trade on?
Compass Therapeutics, Inc. (CMPX) trades on the Nasdaq.
Where is Compass Therapeutics, Inc. incorporated?
Compass Therapeutics, Inc. is incorporated in DE.
When was Compass Therapeutics, Inc. (CMPX)'s most recent SEC filing?
Compass Therapeutics, Inc. (CMPX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CMPX's market cap?
Compass Therapeutics, Inc. (CMPX) has a market capitalization of $409.09M as of 2026-06-30.
What is CMPX's EPS (earnings per share)?
Compass Therapeutics, Inc. (CMPX)'s trailing twelve month EPS is $-0.39 as of 2026-06-30.
What is CMPX's ROE (return on equity)?
Compass Therapeutics, Inc. (CMPX)'s trailing twelve month Return on Equity (ROE) is -56.66% as of 2026-06-30.
What is CMPX's ROA (return on assets)?
Compass Therapeutics, Inc. (CMPX)'s trailing twelve month Return on Assets (ROA) is -47.87% as of 2026-06-30.
What is CMPX's ROIC (return on invested capital)?
Compass Therapeutics, Inc. (CMPX)'s trailing twelve month Return on Invested Capital (ROIC) is -80.70% as of 2026-06-30.
What is CMPX's EV/EBITDA?
Compass Therapeutics, Inc. (CMPX)'s trailing twelve month EV/EBITDA is -4.61x as of 2026-06-30.